

IFW

CASE D0272 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

11-22-06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1647

FRANCO ET AL.

Examiner: GAMETT, DANIEL C.

APPLICATION NO: 10/817,607

FILED: APRIL 2, 2004

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN P2X7 SPLICE
VARIANT, HBMYP2X7V

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, copies of the U.S. patent and U.S. patent publications are not submitted. Copies of foreign patent documents and non-patent literature, if cited, are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289



Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 11-22-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			
Substitute for form 1449/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i>		Application Number	10/817607
		Filing Date	04/02/2004
		First Named Inventor	DIANA FRANCO
		Art Unit	1647
		Examiner Name	GAMETT, DANIEL C
Sheet	2	of	8
		Attorney Docket Number	US - NP

NON PATENT LITERATURE DOCUMENTS			
Examiner - Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Abbracchio, et al., "Purinoreceptors: Are There Families of P2X and P2Y Purinoreceptors", Pharmacol. Ther., Vol. 64, pp. 45-475 (1994)	
	2AB	Adinolfi, et al., "Basal Activation of the P2X ₇ ATP Receptor Elevates Mitochondrial Calcium and Potential, Increases Cellular ATP Levels, and Promotes Serum-independent Growth", Molec. Biol. of the Cell, Vol. 16, pp. 3260-3272 (2005)	
	2AC	Altschul, et al., "Gapped Blast and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., Vol. 25 (17), pp. 3389-3402 (1997)	
	2AD	Atkinson, et al., "An ATP-gated Ion Channel at the Cell Nucleus", Nature, Vol. 420, pp. 42 (2002)	
	2AE	Barden, et al., "Analysis of Single Nucleotide Polymorphisms in Genes in the Chromosome 12Q24.31 Region Points to P2RX7 as a Susceptibility Gene to Bipolar Affective Disorder", Amer. J Med Genet Part B, Vol. 141B, pp. 374-382 (2006)	
	2AF	Barden, et al., "Specific Detection of Non-Functional Human P2X ₇ Receptors in HEK293 Cells and B-lymphocytes", FEBS Ltrs., Vol. 538, pp. 159-162 (2003)	
	2AG	Bianchi, et al., "Pharmacological Characterization of Recombinant Human and Rat P2X Receptor Subtypes", Eur. J. Pharm., Vol. 376, pp. 127-138 (1999)	
	2AH	Budagian, et al., "Signaling through P2X ₇ Receptor in Human T Cells Involves p56 ^{lck} , MAP Kinases, and Transcription Factors AP-1 and NF-κB", J. Biol. Chem., Vol. 278(3), pp. 1549-1560 (2003)	
	2AI	Buell, et al., "Gene Structure and Chromosomal Localization of the Human P2X ₇ Receptor", Receptors Channels., Vol. 5, pp. 347-354 (1998)	
	2AJ	Burnstock G., "Purinergic Nerves", Pharmacol. Reviews, Vol. 24(3), pp. 509-581 (1972)	
	2AK	Cheewatrakoolpong, et al., "Identification and Characterization of Splice Variants of the Human P2X ₇ ATP Channel", Biochem. Biophys. Res. Comm., Vol. 332, pp. 17-27 (2005)	
	2AL	Chessell, et al., "Disruption of the P2X ₇ Purinoreceptor Gene Abolishes Chronic Inflammatory and Neuropathic Pain", Vol. 114, pp. 386-396 (2005)	
	2AM	Denliger, et al., "A Novel Assay to Detect Nucleotide Receptor P2X ₇ Genetic Polymorphisms Influencing Numerous Innate Immune Functions", J. Endotoxin Res., Vol. 10(2), pp. 137-142 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE													
Substitute for form 1449/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i> </div>	<div style="text-align: center; border: 1px solid black; padding: 2px;">COMPLETE IF KNOWN</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Application Number</td> <td style="padding: 2px;">10/817607</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">04/02/2004</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">DIANA FRANCO</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">1647</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">GAMETT, DANIEL C</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">US - NP</td> </tr> </table>	Application Number	10/817607	Filing Date	04/02/2004	First Named Inventor	DIANA FRANCO	Art Unit	1647	Examiner Name	GAMETT, DANIEL C	Attorney Docket Number	US - NP
Application Number	10/817607												
Filing Date	04/02/2004												
First Named Inventor	DIANA FRANCO												
Art Unit	1647												
Examiner Name	GAMETT, DANIEL C												
Attorney Docket Number	US - NP												
Sheet 3 of 8													

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	3AA	Denlinger, et al., "Mutation of a Dibasic Amino Acid Motif Within the C Terminus of the P2X ₇ Nucleotide Receptor Results in Trafficking Defects and Impaired Function", J. Immun., Vol. 171, pp. 1304-1311 (2003)	
	3AB	Elliott, et. al., "The P2X ₇ Receptor is a Candidate Product of Murine and Human Lupus Susceptibility Loci: a Hypothesis and Comparison of Murine Allelic Products", Arthritis Res. Ther., Vol. 7, pp. R468-R475 (2005)	
	3AC	Feng, et al., "ATP Stimulates GRK-3 Phosphorylation and β -Arrestin-2-Dependent Internalization and P2X ₇ Receptor", Am J. Physiol. Cell Physiol., Vol. 288, pp. C1342-C1356 (2005)	
	3AD	Feng, et al., "A Truncated P2X ₇ Receptor Variant (P2X _{7-J}) Endogenously Expressed in Cervical Cancer Cells Antagonizes the Full-Length P2X ₇ Receptor through Hetero-Oligomerization", J. Biol. Chem., Vol. 281(25), pp. 17228-17237 (2006)	
	3AE	Fernando, et al., "Gene Dosage Determines the Negative Effects of Polymorphic Alleles of the P2X ₇ Receptor on Adenosine Triphosphate-Mediated Killing of Mycobacteria by Human Macrophages", J. Infec. Diseases, Vol. 192, pp. 149-155 (2005)	
	3AF	Cabrini, et al., "A His-155 to Tyr Polymorphism Confers Gain-of-Function to the Human P2X ₇ Receptor of Human Leukemic Lymphocytes", J. Immunol., Vol. 175, pp. 82-89 (2005)	
	3AG	Fredholm, et al., "VI. Nomenclature and Classification of Purinoceptors", Pharm. Rev., Vol. 46(2), pp. 143-156 (1994)	
	3AH	Georgiou, et al., "Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X ₇ Receptors", J. Invest. Dermatol., Vol. 125, pp. 482-490 (2005)	
	3AI	Gorodeski, et al., "Estrogen Attenuates P2X ₇ R— Mediated Apoptosis of Uterine Cervical Cells by Blocking Calcium Influx", Nucleosides, Nucleotides & Nucleic Acids, Vol. 23(8/9), pp. 1287-1293 (2004)	
	3AJ	Greig, et al, "Expression of Purinergic Receptors In Non-melanoma Skin Cancers and Their Functional Roles in A431 Cells", J. Invest. Dermatol., Vol. 121, pp. 315-327 (2003)	
	3AK	Greig, et al., "Purinergic Receptors Are Part of a Functional Signaling System for Proliferation and Differentiation of Human Epidermal Keratinocytes", J. Invest. Dermatol., Vol. 120, pp. 1007-1015 (2003)	
	3AL	Gu, et al., "An Arg ³⁰⁷ to Gln Polymorphism within the ATP-Binding Site Causes Loss of Function of the Human P2X ₇ Receptor", J. Biol. Chem., Vol. 279(30), pp. 31287-31295 (2004)	
	3AM	Gu, et al., "Rapid ATP-Induced Release of Matrix Metalloproteinase 9 is Mediated by the P2X ₇ Receptor", Blood, Vol. 107(12), pp. 4946-4953 (2006)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			
Substitute for form 1449/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i>		Application Number	10/817607
		Filing Date	04/02/2004
		First Named Inventor	DIANA FRANCO
		Art Unit	1647
		Examiner Name	GAMETT, DANIEL C
Sheet	4	of	8
		Attorney Docket Number	US - NP

NON PATENT LITERATURE DOCUMENTS			
Examiner - Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	4AA	Kim, et al., "Proteomic and Functional Evidence for a P2X ₇ Receptor Signalling Complex", EMBO J., Vol. 20(22), pp. 6347-6358 (2001)	
	4AB	Le, et al., "Primary Structure and Expression of a Naturally Truncated Human P2X ATP Receptor Subunit from Brain and Immune System", FEBS Ltrs., Vol. 418, pp. 195-199 (1997)	
	4AC	Li, et al., "Regulation of the P2X ₇ Receptor Permeability to Large Molecules by Extracellular C1 ⁻ and Na ⁺ ", J. Biol. Chem., Vol. 280(29), pp. 26922-26927 (2005)	
	4AD	Longhurst, et al., "The Human P _{2X1} Receptor: Molecular Cloning, Tissue Distribution, and Localization to Chromosome 17", Biochim. Biophys. Acta, Vol. 1308, pp. 185-188 (1996)	
	4AE	Lynch, et al., "Molecular and Functional Characterization of Human P2X ₂ Receptors", Molec. Pharmacol., Vol. 56, pp. 1171-1181 (1999)	
	4AF	Mammalian Gene Collection (MGC) Program Team, "Generation and Initial Analysis of More than 15,000 Full-Length Human and Mouse cDNA Sequences", PNAS, Vol. 99(26), pp. 16899-16903 (2002)	
	4AG	Narcisse, et al., "The Cytokine IL-1 β Transiently Enhances P2X ₇ Receptor Expression and Function in Human Astrocytes", GLIA, Vol. 49, pp. 245-258 (2005)	
	4AH	North Alan R., "Molecular Physiology of P2X Receptors", Physiol. Rev., Vol. 82, pp. 1013-1067 (2002)	
	4AI	Nuckel, et al., "1513A/C Polymorphism in the P2X ₇ Receptor Gene in Chronic Lymphocytic Leukemia: Absence of Correlation with Clinical Outcome", Eur. J. Haematol, Vol. 72, pp. 259-263 (2004)	
	4AJ	Parvathani, et al., "P2X ₇ Mediates Superoxide Production in Primary Microglia and Is Up-Regulated in a Transgenic Mouse Model of Alzheimer's Disease", J. Biol. Chem., Vol. 278(15), pp. 13309-13317 (2003)	
	4AK	Penolazzi, et al., "N-Arylpiperazine modified analogues of the P2X ₇ receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts", J. Biomed. Science, Vol. 12, pp. 1013-1020 (2005)	
	4AL	Raffaghello, et al., "The P2X ₇ Receptor Sustains the Growth of Human Neuroblastoma Cells through a Substance P-Dependent Mechanism", Cancer Res., Vol. 66(2), pp. 907-914 (2006)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/817607
Filing Date	04/02/2004
First Named Inventor	DIANA FRANCO
Art Unit	1647
Examiner Name	GAMETT, DANIEL C
Attorney Docket Number	US - NP

Sheet

5

of

8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	5AA	Ralevic, et al., "Receptors for Purines and Pyrimidines", Pharm. Reviews, Vol. 50(3), pp. 413-492 (1998)	
	5AB	Rassendren, et al., "The Permeabilizing ATP Receptor, P2X ₇ ", J. Biol. Chem., Vol. 272(9), pp. 5482-5486 (1997)	
	5AC	Saunders, et al., "A Loss-of-Function Polymorphism in the Human P2X ₇ Receptor Abolishes ATP-Mediated Killing of Mycobacteria", J. Immunol., Vol. 171, pp. 5442-5446 (2003)	
	5AD	Sengstake, et al., "CD21 and CD62L Shedding are Both Inducible via P2X ₇ Rs", Internat. Immunol, Vol. 18(7), pp. 1171-1178 (2006)	
	5AE	Shemon, et al., "A Thr ³⁵⁷ to Ser Polymorphism in Homozygous and Compound Heterozygous Subjects Causes Absent or Reduced P2X ₇ Function and Impairs ATP-Induced Mycobacterial Killing by Macrophages", J. Biol. Chem., Vol. 281(4), pp. 2079-2086 (2006)	
	5AF	Skarratt, et al., "A 5' Intronic Splice Site Polymorphism Leads to a Null Allele of the P2X ₇ Gene in 1-2% of the Caucasian Population", FEBS Ltrs, Vol. 579, pp. 2675-2678 (2005)	
	5AG	Sluyter, et al., "Glu ⁴⁹⁶ to Ala Polymorphism in the P2X ₇ Receptor Impairs ATP-Induced IL-1 β Release from Human Monocytes", J. Immunol., Vol. 172, pp. 3399-3405 (2004)	
	5AH	Sluyter, et al., "Extracellular Adenosine 5'-Triphosphate Induces a Loss of CD23 from Human Dendritic Cells via Activation of P2X ₇ Receptors", Intern. Immunol., Vol. 14(12), pp. 1415-1421 (2002)	
	5AI	Sluyter, et al., "Extracellular ATP Increases Cation Fluxes in Human Erythrocytes by Activation of the P2X ₇ Receptor", J. Biol. Chem., Vol. 279(43), pp. 44749-44755 (2004)	
	5AJ	Solini, et al., "Enhanced P2X ₇ Activity in Human Fibroblasts From Diabetic Patients", Arterioscler Thromb Vasc. Biol., Vol. 24, pp. 1240-1245 (2004)	
	5AK	Straub R.W. and Bolis Liana, Editors, "Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach", Raven Press, New York, 1978, pp. 107-118, "A Basis for Distinguishing Two Types of Purinergic Receptor"	
	5AL	Sun, et al., "P2X ₁ Purinoceptor in Human Platelets", J. Biol. Chem., Vol. 273(19) pp. 11544-11547 (1998)	
	5AM	Urano, et al., "Cloning of P2XM, a Novel Human P2X Receptor Gene Regulated by p53", Can. Res., Vol. 57, pp. 3281-3287 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE															
Substitute for form 1449/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i> </div>		<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;"> COMPLETE IF KNOWN </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/817607</td> </tr> <tr> <td>Filing Date</td> <td>04/02/2004</td> </tr> <tr> <td>First Named Inventor</td> <td>DIANA FRANCO</td> </tr> <tr> <td>Art Unit</td> <td>1647</td> </tr> <tr> <td>Examiner Name</td> <td>GAMETT, DANIEL C</td> </tr> <tr> <td>Attorney Docket Number</td> <td>US - NP</td> </tr> </table>		Application Number	10/817607	Filing Date	04/02/2004	First Named Inventor	DIANA FRANCO	Art Unit	1647	Examiner Name	GAMETT, DANIEL C	Attorney Docket Number	US - NP
Application Number	10/817607														
Filing Date	04/02/2004														
First Named Inventor	DIANA FRANCO														
Art Unit	1647														
Examiner Name	GAMETT, DANIEL C														
Attorney Docket Number	US - NP														
Sheet	6	of	8												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	6AA	Valera, et al, "Characterization and Chromosomal Localization of a Human P _{2x} Receptor from the Urinary Bladder", Receptors Channels, Vol. 3, pp. 283-289 (1995)	
	6AB	Verhoef, et al., "P2X ₇ Receptor-Dependent Blebbing and the Activation of Rho-Effector Kinases, Caspases, and IL-1 β Release", J. Immun., Vol. 170, pp. 5728-5738 (2003)	
	6AC	White, et al., "Human Melanomas Express Functional P2X ₇ Receptors", Cell Tissue Res., Vol. 321, pp. 411-418 (2005)	
	6AD	Wiley, et al., "An Ile-568 to Asn Polymorphism Prevents Normal Trafficking and Function of the Human P2X ₇ Receptor", J. Biol. Chem., Vol. 278(19), pp. 17108-17113 (2003)	
	6AE	Wiley, et al., "A Loss-of-Function Polymorphic Mutation in the Cytolytic P2X ₇ Receptor Gene and Chronic Lymphocytic Leukaemia: a Molecular Study", The Lancet, Vol. 359, pp. 1114-1119 (2002)	
	6AF	Wilson, et al., "Epithelial Membrane Proteins Induce Membrane Blebbing and Interact with the P2X ₇ Receptor C Terminus", J. Biol. Chem., Vol. 277(37), pp. 34017-34029 (2002)	
	6AG	Witting, et al., "P2X ₇ Receptors Control 2-Arachidonoylglycerol Production by Microglial Cells", PNAS, Vol. 101(9), pp. 3214-3219 (2004)	
	6AH	Worthington, et al., "Point Mutations Confer Loss of ATP-Induced Human P2X ₇ Receptor Function", Febs Ltrs., Vol. 512, pp. 43-46 (2002)	
	6AI	Zhang, et al., "Expression of P2X ₇ In Human Hematopoietic Cell Lines and Leukemia Patients", Leukemia Res., Vol. 28, pp. 1313-1322 (2004)	
	6AJ	Zhang, et al., "P2X ₇ Polymorphism and Chronic Lymphocytic Leukaemia: Lack of Correlation with Incidence, Survival and Abnormalities of Chromosome 12", Vol. 17, pp. 2097-2100 (2003)	
	6AK	NCBI Entrez Accession No. AAH11913 (gi:15080309), Strausberg, et al., July 15, 2006	
	6AL	NCBI Entrez Accession No. AAX82093 (gi:62420453), Cheewatrakoolpong, et al., May 29, 2005	
	6AM	NCBI Entrez Accession No. CAA70755 (gi:1854512) Rassendren, et al., March 14, 1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/817607
Filing Date	04/02/2004
First Named Inventor	DIANA FRANCO
Art Unit	1647
Examiner Name	GAMETT, DANIEL C
Attorney Docket Number	US - NP

Sheet **7** of **8**

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	7AA	NCBI Entrez Accession No. CAA73360 (gi:2597927), Buell, et al., November 14, 2006	
	7AB	NCBI Entrez Accession No. NP_002553 (gi:29294631), Sengstake, et al., October 15, 2006	
	7AC	NCBI Entrez Accession No. NM_002562 (gi:34335273), Sengstake, et al., October 15, 2006	
	7AD	NCBI Entrez Accession No. NP_803177 (gi:34222250), Greig, et al., August 26, 2003	
	7AE	NCBI Entrez Accession No. NP_803176 (gi:29294633), Shemon, et al., March 19, 2006	
	7AF	NCBI Entrez Accession No. Q99572 (gi:3915804), Rassendren, et al., November 14, 2006	
	7AG	NCBI Entrez Accession No. XM_052953 (gi:15308484), NCBI Annotation Project, October 16, 2001	
	7AH	NCBI Entrez Accession No. XP_001163832 (gi:114647402), NCBI Annotation Process, September 15, 2006	
	7AI	NCBI Entrez Accession No. XP_001163687 (gi:114647400), NCBI's Annotation Process, September 15, 2006	
	7AJ	NCBI Entrez Accession No. XP_001163756 (gi:114647404), NCBI's Annotation Process, September 15, 2006	
	7AK	NCBI Entrez Accession No. XP_001163797 (gi:114647398), NCBI's Annotation Process, September 15, 2006	
	7AL	NCBI Entrez Accession No. XP_001163873 (gi:114647396), NCBI's Annotation Process, September 15, 2006	
	7AM	NCBI Entrez Accession No. XP_012121 (gi:14768227), NCBI's Annotation Project, October 16, 2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/817607
Filing Date	04/02/2004
First Named Inventor	DIANA FRANCO
Art Unit	1647
Examiner Name	GAMETT, DANIEL C
Attorney Docket Number	US - NP

Sheet **8** of **8**

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	8AA	NCBI Entrez Accession No. XP_509436 (gi:114647394), NCBI's Annotation Process, September 15, 2006	
	8AB	Swiss-Prot Accession No. O15547, December 15, 1998	
	8AC	Swiss-Prot Accession No. P51575, October 1, 1996	
	8AD	Swiss-Prot Accession No. P56373, July 15, 1998	
	8AE	Swiss-Prot Accession No. Q64663, November 1, 1997	
	8AF	Swiss-Prot Accession No. Q93086, November 1, 1997	
	8AG	Swiss-Prot Accession No. Q99571, November 1, 1997	
	8AH	Swiss-Prot Accession No. Q99572, November 1, 1997	
	8AI	Swiss-Prot Accession No. Q9UBL9, January 24, 2001	
	8AJ	Swiss-Prot Accession No. Q9Z1M0, May 30, 2000	
	8AK	Denlinger, et al., "Detection of Human P2X ₇ Nucleotide Receptor Polymorphisms by a Novel Monocyte Pore Assay Predictive of Alterations in Lipopolysaccharide-Induced Cytokine Production", J. Immun., Vol. 174, pp. 4424-4431 (2005)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant



Case No.: D0272 WP
Application No.: 101817,607
Mailing Date: 11/22/06
Express Mail No.: _____

The Patent & Trademark Office acknowledges, and has stamped hereon the date of receipt of the items checked below:

- ☐ Transmittal Letter
 - ☐ Provisional
 - ☐ Non-provisional
 - ☐ CIP ☐ DIV ☐ CONT
 - ☐ RCE
- ☐ Specification _____ pages
- ☐ Drawings _____ pages
- ☐ Sequence Listing _____ pages/disk
- ☐ Statement of Verification
- ☐ Preliminary Amendment
- ☐ Executed/Unexecuted Declaration
- ☐ Response to Missing Parts
- ☐ Assignment Recordation Request
- ☐ Response to Restriction Requirement
- ☒ IDS (2 pgs)
- ☒ 1449 Form 8 pages
- ☒ No. Of References 102
- ☐ Amendment/Response/Letter
- ☐ Amendment After Final
- ☐ Petition For Extension of Time
- ☐ Notice of Appeal
- ☐ Appeal Brief
- ☐ Issue Fee Payment
- ☐ Other _____

FM060019-1

SCP